[vc_row][vc_column][vc_column_text] Assorted news from last week: The White House announced the reigniting of the Cancer Moonshot on February 2. Two prominent items related to the
[vc_row][vc_column][vc_column_text] Assorted news from last week: Retinoblastoma treatment outcomes have improved globally over the past four decades but large disparities persist between higher-income and lower-income
Assorted news from the last two weeks: Adolescents and young adult cancer survivors are more likely to have psychological distress and additional annual medical expenses
Assorted news from the last two weeks: Children with chronic health conditions, including cancer, and those with special education needs, should receive more help with
Assorted news from the last two weeks: The FDA has granted rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening cancer
Assorted news from last week: From the Lancet: Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally
[vc_row][vc_column][vc_column_text] Assorted news from last week: Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival
Assorted news from last week: According to Jim Morris, investigative reporter for Public Health Watch, “for the foreseeable future, thousands of children will continue to
Assorted news from last week: A primer on where the Centers for Medicare and Medicaid Services see Medicaid and the Children’s Health Insurance Program (CHIP)
Assorted news from last week: Provocative article written by pediatric cancer advocates, including several CAC2 members — innovation can be crippled by commercialization — meaning
